Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-400945 in Relapsed or Refractory AML or MDS
NCT03187288Phase 1Completed
- Sponsor
- University Health Network
- Start
- May 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ocifisertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University Health Network. Primary endpoints: Treatment-Emergent Adverse Events at 5 years, Maximum Tolerated Dose at 5 years and 1 more. Started May 2018; status: completed.
02
Drugs
ocifisertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03187288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187288.